Since 1995, we have built a 29-year legacy of expertise, experience and trust with patients, doctors, and healthcare providers by offering quality diagnostics and continually upgrading our technology to meet evolving customer needs. Our diagnostics laboratory network follows a 'hub-and-spoke' model, where specimens are collected from multiple locations and sent to our reference labs for centralized testing
In fiscal 2023, Agilus Diagnostics served 16.62 million patients and conducted an average of 107,043 diagnostic tests daily. As of March 31, 2023, our diagnostics laboratory network is supported by 4,614 medical and scientific professionals, including 438 doctors and 4,176 technicians and paramedical staff.
Global Reference Lab & 5 Regional Labs
Centers of
Excellence
Radiology and 25 Wellness Centers
NABL and 2 CAP Accredited Labs
We offer over 3,800 routine and specialized diagnostics tests, including tests in genomics, molecular pathology for cancer, reproductive medicine, rare diseases and inherited disorders.
1. Pathology tests ranging from routine (biochemistry, haematology, microbiology, genetics, immunology, clinical pathology) to specialized (advanced molecular diagnostics, protein chemistry, cellular immunology, flow cytometry, genetics, cytogenetics, immunohistochemistry, advanced microbiology).
2. Radiology tests from routine (echocardiograms, X-rays, ultrasounds) to advanced (MRI, CT).
Our technology infrastructure is supported by logistics efficiencies, such as route planning and optimization, integrated systems for registration (bar-coding), billing, analysis reporting and delivery of reports that enable us to reduce human error, deliver faster TAT and enhance customer experience. We are committed to delivering a customer-centric experience through an integrated and seamless customer experience enabled through our technology platforms and data-driven actionable insights.
We focus on R&D to ensure accurate and timely diagnosis, helping patients and healthcare providers address growing health challenges. Our R&D division explores new business areas like pharmacogenomics and preventive medicine, expands its existing test menu and develops new tests and assays in diagnostics, in order to improve sensitivity, specificity, time or costs as compared to available conventional tools. In particular, we focus on developing advanced solutions in diagnostics testing, laboratory efficiency and clinical decision support with a special focus on genomics and next-generation diagnostics. Our R&D team also undertakes clinical research studies, co-marketing projects, contract evaluation and collaborations with various national laboratory network, technology providers and other advanced research centers on various areas with direct or indirect impact on healthcare. We regularly participate in scientific and academic conferences in India which has helped us in strengthening our brand recall and relationship with doctors. We are supported by a scientific team led by Dr. Avinash Phadke (President – Technical and Mentor, Clinical Pathology).
We derive benefit from the lineage of our Promoter, Fortis Healthcare Ltd., by leveraging its long-standing legacy in healthcare services, in-depth understanding, and operational experience, in the healthcare industry, corporate governance standards, values and trust. Fortis is one of the leading players in the Indian healthcare delivery market in India. . The experience and diversity of our management team and Board of Directors give us the ability to operate successfully in our competitive industry and in the changing market environment, implement our strategies and successfully integrate any acquired businesses.
© 2025 Agilus Diagnostics | All Rights Reserved.